Hereditary Hematologic Malignancy Assessment: Making it Mainstream

On February 9th, 2022, RRP and Invitae partnered to present this webinar on assessing hereditary hematologic malignancy to genetic counselors, hematologic oncologists, hematologists, oncologists and related healthcare providers.

Webinar Content:

Presentation by Sarah Bannon, a Genetic Counselor at Genome Medical who specializes in hereditary predispositions to cancer (03:17).

Presentation by Dr. Lucy Godley, a physician-scientist at the University of Chicago School of Medicine who specializes in the care and treatment of patients with diseases of the bone marrow, including leukemias, lymphomas and multiple myeloma (29:15).

Webinar Learning Objectives:

• List three clinical indications for hereditary hematologic malignancy assessment.

• Compare and contrast the clinical and familial presentations among RUNX1, CEBPA and DDX41.

• Identify the ideal specimen source for hereditary hematologic malignancy susceptibility testing, given an individual’s clinical presentation.

• Describe potential management implications when identifying an individual with an active hereditary hematologic malignancy.

Previous

Hereditary Hematologic Malignancies: Not That Rare - Dr. Courtney DiNardo

Next

RUNX1 Deficiency in Megakaryopoiesis: Discovering Therapeutics for RUNX1 Haploinsufficiency